-$0.34 EPS Expected for Sarepta Therapeutics Inc (SRPT) This Quarter

Analysts expect Sarepta Therapeutics Inc (NASDAQ:SRPT) to report earnings of ($0.34) per share for the current fiscal quarter, Zacks reports. Nine analysts have made estimates for Sarepta Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.21) and the lowest estimate coming in at ($0.52). Sarepta Therapeutics posted earnings per share of ($0.78) in the same quarter last year, which indicates a positive year over year growth rate of 56.4%. The company is scheduled to issue its next earnings report on Wednesday, October 24th.

According to Zacks, analysts expect that Sarepta Therapeutics will report full-year earnings of ($1.77) per share for the current fiscal year, with EPS estimates ranging from ($2.98) to ($1.28). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.40) per share, with EPS estimates ranging from ($2.77) to ($0.45). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Sarepta Therapeutics.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($1.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.99). Sarepta Therapeutics had a negative return on equity of 19.34% and a negative net margin of 89.64%. The company had revenue of $73.53 million during the quarter, compared to the consensus estimate of $71.53 million. During the same quarter in the prior year, the firm earned ($0.48) earnings per share. The business’s revenue was up 110.0% compared to the same quarter last year.

A number of analysts have recently commented on SRPT shares. HC Wainwright set a $267.00 price target on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, July 18th. BidaskClub upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, August 24th. JPMorgan Chase & Co. restated an “overweight” rating on shares of Sarepta Therapeutics in a research report on Tuesday, June 19th. Bank of America initiated coverage on shares of Sarepta Therapeutics in a research report on Friday, September 14th. They set a “buy” rating and a $199.00 target price for the company. Finally, Zacks Investment Research upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, July 6th. Two investment analysts have rated the stock with a hold rating, twenty-five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $169.28.

In other news, CEO Douglas S. Ingram purchased 16,000 shares of the stock in a transaction on Wednesday, August 15th. The shares were acquired at an average price of $125.26 per share, with a total value of $2,004,160.00. Following the completion of the acquisition, the chief executive officer now directly owns 399,250 shares of the company’s stock, valued at $50,010,055. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.90% of the stock is owned by insiders.

Large investors have recently modified their holdings of the business. Kovack Advisors Inc. purchased a new position in Sarepta Therapeutics during the second quarter valued at approximately $217,000. Catalyst Capital Advisors LLC purchased a new position in Sarepta Therapeutics during the second quarter valued at approximately $2,445,000. State of Alaska Department of Revenue purchased a new position in Sarepta Therapeutics during the second quarter valued at approximately $993,000. World Asset Management Inc purchased a new position in Sarepta Therapeutics during the second quarter valued at approximately $287,000. Finally, Columbus Circle Investors purchased a new position in Sarepta Therapeutics during the second quarter valued at approximately $3,539,000. 89.99% of the stock is currently owned by institutional investors and hedge funds.

Shares of SRPT stock traded up $1.49 during trading hours on Wednesday, reaching $140.07. The company had a trading volume of 25,660 shares, compared to its average volume of 1,453,345. Sarepta Therapeutics has a one year low of $46.07 and a one year high of $176.50. The firm has a market capitalization of $10.73 billion, a PE ratio of -85.51 and a beta of 1.15. The company has a quick ratio of 9.89, a current ratio of 10.88 and a debt-to-equity ratio of 0.62.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

Recommended Story: Asset Allocation and Your Retirement

Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply